EP0858340A4 - Traitement combine du diabete et de l'obesite - Google Patents

Traitement combine du diabete et de l'obesite

Info

Publication number
EP0858340A4
EP0858340A4 EP96937097A EP96937097A EP0858340A4 EP 0858340 A4 EP0858340 A4 EP 0858340A4 EP 96937097 A EP96937097 A EP 96937097A EP 96937097 A EP96937097 A EP 96937097A EP 0858340 A4 EP0858340 A4 EP 0858340A4
Authority
EP
European Patent Office
Prior art keywords
obesity
combination therapy
treating diabetes
diabetes
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96937097A
Other languages
German (de)
English (en)
Other versions
EP0858340A1 (fr
Inventor
Roy G Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603724.7A external-priority patent/GB9603724D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0858340A1 publication Critical patent/EP0858340A1/fr
Publication of EP0858340A4 publication Critical patent/EP0858340A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP96937097A 1995-11-01 1996-10-31 Traitement combine du diabete et de l'obesite Withdrawn EP0858340A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US713895P 1995-11-01 1995-11-01
US7138P 1995-11-01
GBGB9603724.7A GB9603724D0 (en) 1996-02-22 1996-02-22 Combinatyion therapy for the treatment of diabebes and obesity
GB9603724 1996-02-22
PCT/US1996/017444 WO1997016189A1 (fr) 1995-11-01 1996-10-31 Traitement combine du diabete et de l'obesite

Publications (2)

Publication Number Publication Date
EP0858340A1 EP0858340A1 (fr) 1998-08-19
EP0858340A4 true EP0858340A4 (fr) 1999-12-29

Family

ID=26308780

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96937097A Withdrawn EP0858340A4 (fr) 1995-11-01 1996-10-31 Traitement combine du diabete et de l'obesite

Country Status (4)

Country Link
EP (1) EP0858340A4 (fr)
JP (1) JPH11515027A (fr)
AU (1) AU7484596A (fr)
WO (1) WO1997016189A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
WO1997026011A1 (fr) * 1996-01-19 1997-07-24 Eli Lilly And Company Formulations de proteine de l'obesite
JP2001501177A (ja) * 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法
AU723879C (en) * 1996-10-31 2003-11-06 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
EP0920864A1 (fr) * 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne
EP1153919A4 (fr) 1999-02-16 2002-10-02 Kaneka Corp Derives d'acetylpyridine substituee et procede de preparation d'intermediaires pour agoniste du recepteur adrenergique beta3 optiquement actif, faisant appel a ces derives
JP2004331500A (ja) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd 血中濃度制御製剤
JPWO2003033468A1 (ja) * 2001-10-17 2005-02-03 株式会社カネカ （Ｓ）−α−ハロメチルピリジンメタノール誘導体の製造方法
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (fr) * 1993-02-09 1994-08-17 Merck & Co. Inc. Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité
WO1995029159A1 (fr) * 1994-04-26 1995-11-02 Merck & Co., Inc. SULFAMIDES SUBSTITUES UTILISES COMME AGONISTES SELECTIFS VIS-A-VIS DES RECEPTEURS β3-ADRENERGIQUES, POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE
EP0920864A1 (fr) * 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (fr) * 1993-02-09 1994-08-17 Merck & Co. Inc. Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité
WO1995029159A1 (fr) * 1994-04-26 1995-11-02 Merck & Co., Inc. SULFAMIDES SUBSTITUES UTILISES COMME AGONISTES SELECTIFS VIS-A-VIS DES RECEPTEURS β3-ADRENERGIQUES, POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE
EP0920864A1 (fr) * 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9716189A1 *

Also Published As

Publication number Publication date
WO1997016189A1 (fr) 1997-05-09
JPH11515027A (ja) 1999-12-21
EP0858340A1 (fr) 1998-08-19
AU7484596A (en) 1997-05-22

Similar Documents

Publication Publication Date Title
DE69715631D1 (de) Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit
ATA46794A (de) Einrichtung zur behandlung von hautzonen
DE69324625D1 (de) Vorrichtung zur Behandlung von Fettleibigkeit und motorischen Störungen des Magens
DE69731736D1 (de) Injektionsbehandlung zur beherrschung von muskelkrämpfen und damit einhergehenden schmerzen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
FI964314A7 (fi) Substituoidut sulfonamidit selektiivisinä beta3-agonisteina diabeteksen ja liikalihavuuden hoitoon
EP0998262A4 (fr) Isoflavono de utilise pour traiter et prevenir le vieillissement de la peau et les rides
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
DE69827424D1 (de) Vorrichtung zur gesteuerten thermischen Behandlung von Gewebe
ATE275383T1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
DE69609868D1 (de) Neue steroidester zur behandlung von hauterkrankungen
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE69731515D1 (de) Gerät zur Behandlung fotoempfindlichen Materials
DE69526390D1 (de) Kugelförmige Aktivkohle zur Behandlung von Stoma-peripherer Entzündung
FI963252L (fi) Kivun hoitoon tarkoitetut uudet opioidipeptidit ja niiden käyttö
DE69711311D1 (de) Vorrichtung zur thermischen Behandlung von Gewebe
ATE227127T1 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
DE69630321D1 (de) Vorrichtung zur örtlichen wärmebehandlung von gewebe
EP1043983A4 (fr) Tetracycline et/ou un ou plusieurs derives de tetracycline pour traiter, supprimer ou prevenir des maladies cerebrovasculaires du systeme nerveux
DE69506019D1 (de) Vorrichtung zur Behandlung von Schmerz
EP0795035A4 (fr) Traitement des peaux
DE69836209D1 (de) Vorbeugung und behandlunhg des hepatozellulären krebses
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991115

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61K 31/44 A, 6A 61K 38/18 B, 6A 61K 38/17 B, 6A 61K 38/22 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010501